Showing results (1151-1160 of 1,170) with videos related to
Sort By:
Pageof 117
Cancer Research|April 17, 2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasisSuzanne A Eccles, Andy Massey, Florence I Raynaud, et al.Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapyMohammed Altaf, Carla Nel, Timothy Tipoe, et al.Journal of Medicinal Chemistry|June 2, 2022
Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In VivoRosemary Huckvale, Alice C Harnden, Kwai-Ming J Cheung, et al.Nature Communications|June 8, 2026
5' leader defects drive persistent HIV-1 viremia on long-term ARTJulia R Box, Angelica Camilo-Contreras, Filippo Dragoni, et al.Journal of Medicinal Chemistry|August 30, 2008
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancerAdrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, et al.Journal of Medicinal Chemistry|October 2, 2014
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptorM Raymond V Finlay, Mark Anderton, Susan Ashton, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2023
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023Kelvin A Moses, Preston C Sprenkle, Clinton Bahler, et al.Science (New York, N.Y.)|November 6, 2025
Postdomestication selection of MKK3 shaped seed dormancy and end-use traits in barleyMorten E Jørgensen, Dominique Vequaud, Yucheng Wang, et al.Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO TrialMing Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.The Lancet. HIV|May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trialMing J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.Pageof 117